NGMD:CA:TSV-NuGen Medical Devices Inc (CAD)

COMMON STOCK | Medical Devices |

Last Closing

USD 0.085

Change

0.00 (0.00)%

Market Cap

USD 0.02B

Volume

0.01M

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NuGen Medical Devices Inc., a specialty medical device company, develops and commercializes novel drug delivery technologies in Europe, Asia, North America, and internationally. The company offers needle-free injection devices and systems for the administration of subcutaneous medication for various fields, including diabetes, semaglutide, and growth and fertility hormone, as well as DNA and conventional/pediatric vaccines. It also provides InsuJet system that focuses on servicing the diabetic community; and V5, V6, V7, and V8 InsuJet injectors. NuGen Medical Devices Inc. is headquartered in Toronto, Canada.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Medical Devices

Symbol Name Price(Change) Market Cap
TLT:CA Theralase Technologies Inc.

-0.01 (-1.64%)

USD 0.07B
PINK:CA Perimeter Medical Imaging AI I..

+0.03 (+6.02%)

USD 0.05B
ASG:CA Aurora Spine Corp

+0.01 (+2.13%)

USD 0.03B
MDX:CA MedX Health Corp

N/A

USD 0.02B
VPT:CA VentriPoint Diagnostics Ltd

+0.01 (+4.76%)

USD 0.02B
THRM:CA Therma Bright Inc

-0.01 (-12.50%)

USD 0.01B
EVMT:CA Evome Medical Technologies Inc..

+0.01 (+3.45%)

USD 0.01B
FREQ:CA Frequency Exchange Corp.

N/A

USD 0.01B
CNVI:CA Conavi Medical Corp.

-0.05 (-7.35%)

N/A

ETFs Containing NGMD:CA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Medical Devices) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 13.33% 44% F 67% D+
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.33% 44% F 67% D+
Trailing 12 Months  
Capital Gain -26.09% 38% F 43% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -26.09% 38% F 43% F
Trailing 5 Years  
Capital Gain N/A N/A N/A N/A N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return N/A N/A N/A N/A N/A
Average Annual (5 Year Horizon)  
Capital Gain 2.53% 38% F 54% F
Dividend Return 2.53% 38% F 53% F
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 55.20% 63% D 49% F
Risk Adjusted Return 4.59% 38% F 53% F
Market Capitalization 0.02B 56% F 66% D+

Annual Financials (CAD)

Quarterly Financials (CAD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.